Our Vision
To bring transformational new drugs to eye care and other specialties, starting with Demodex Blepharitis.
About Demodex Blepharitis
Demodex mite infestation is implicated as a cause of 45% of blepharitis, a common ocular condition.
Learn More
About
TP-03
TP-03 is a novel drug that targets the Demodex mite nervous system to kill the mites, thereby treating the underlying cause of disease.
Learn More
About
Tarsus
Tarsus is a privately held, clinical-stage biopharmaceutical company founded in 2017 and headquartered in Irvine, CA.
Learn More
See How Demodex Mites Cause Disease
News
Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Enrollment and Treatment in Phase 2b/3 Saturn-1 Trial
Phase 2 trials Io and Europa meet endpoints for novel ophthalmic therapeutic targeting Demodex mites; Saturn-1 pivotal trial enrollment now underway
Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters
Mr. Mottiwala Brings over 20 Years of Biopharmaceutical Experience to Growing Tarsus Leadership Team
Tarsus Pharmaceuticals Announces Appointment of New COO and CFO
Sesha Neervannan, PhD, to assume position of Chief Operating Officer; Leo Greenstein to assume position of Chief Financial Officer